Phase 1 Melanoma Trial, Recruiting NCT03819296 Sponsor: M.D. Anderson Cancer Center Condition: Melanoma
Back to Melanoma

Phase 1 Melanoma Trial, Recruiting

NCT03819296
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with melanoma, non-small cell lung cancer, or a urinary/reproductive system cancer (any stage), or any type of cancer depending on which part of the study you join
  • You are currently being treated with a type of immunotherapy called an immune checkpoint inhibitor (a cancer drug that works with your immune system)
  • You are willing and able to read, understand, and sign a consent form and complete surveys
  • You have a life expectancy of more than 4 months (for one part of the study)
  • You are experiencing diarrhea and/or bowel inflammation (colitis) as a side effect of your immunotherapy treatment (for some parts of the study)
  • Your diarrhea/colitis side effects are moderate to severe and you are receiving, or have received, treatments such as steroids or other immune-suppressing medicines (for some parts of the study)
  • Your diarrhea/colitis has not responded to steroids and at least two other immune-suppressing medicines, OR you cannot take immune-suppressing medicines, OR your symptoms came back after treatment, OR your symptoms return when steroids are reduced or stopped (for one specific part of the study)
  • You have no signs of an active gut infection at the time of joining the study, confirmed by stool tests or your doctor's assessment (for one part of the study)
  • You have been cleared by an infectious disease doctor or your treating doctor if any infection screening test came back positive (for one part of the study)

Who may not be able to join:

  • You are under 18 years old
  • You have a history of inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) or bowel damage from radiation that is currently active
  • You are pregnant or breastfeeding
  • You are a woman who could become pregnant and either test positive on a pregnancy test, or decline to take one (unless you have not had a period for over a year, your doctor has documented you are near or past menopause, or there is recent evidence confirming you are not pregnant)
  • You develop side effects affecting organs outside the digestive system around the time of a procedure called a fecal transplant (for one part of the study)
  • You have an active bacterial or fungal infection (for one part of the study)
  • A stool donor connected to your treatment is assessed as being at risk for monkeypox infection or exposure (for one part of the study)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yinghong Wang, M.D. Anderson Cancer Center

Phone: 713-563-6086

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
21 February 2021
Est. completion
31 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Difference in stool microbiome pattern; Incidence of adverse events (AE) of fecal microbiota transplantation (FMT) (Project 3)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov